Cargando…

QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data

INTRODUCTION: Hydroxychloroquine can induce QT/QTc interval prolongation for some patients; however, little is known about its interactions with other QT-prolonging drugs. OBJECTIVE: The purpose of this retrospective electronic health records study was to evaluate changes in the QTc interval in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Villa Zapata, Lorenzo, Boyce, Richard D., Chou, Eric, Hansten, Philip D., Horn, John R., Gephart, Sheila M., Subbian, Vignesh, Romero, Andrew, Malone, Daniel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167427/
https://www.ncbi.nlm.nih.gov/pubmed/35665910
http://dx.doi.org/10.1007/s40801-022-00307-5
_version_ 1784720795314946048
author Villa Zapata, Lorenzo
Boyce, Richard D.
Chou, Eric
Hansten, Philip D.
Horn, John R.
Gephart, Sheila M.
Subbian, Vignesh
Romero, Andrew
Malone, Daniel C.
author_facet Villa Zapata, Lorenzo
Boyce, Richard D.
Chou, Eric
Hansten, Philip D.
Horn, John R.
Gephart, Sheila M.
Subbian, Vignesh
Romero, Andrew
Malone, Daniel C.
author_sort Villa Zapata, Lorenzo
collection PubMed
description INTRODUCTION: Hydroxychloroquine can induce QT/QTc interval prolongation for some patients; however, little is known about its interactions with other QT-prolonging drugs. OBJECTIVE: The purpose of this retrospective electronic health records study was to evaluate changes in the QTc interval in patients taking hydroxychloroquine with or without concomitant QT-prolonging medications. METHODS: De-identified health records were obtained from the Cerner Health Facts(®) database. Variables of interest included demographics, diagnoses, clinical procedures, laboratory tests, and medications. Patients were categorized into six cohorts based on exposure to hydroxychloroquine, methotrexate, or sulfasalazine alone, or the combination of any those drugs with any concomitant drug known to prolong the QT interval. Tisdale QTc risk score was calculated for each patient cohort. Two-sample paired t-tests were used to test differences between the mean before and after QTc measurements within each group and ANOVA was used to test for significant differences across the cohort means. RESULTS: A statistically significant increase in QTc interval from the last measurement prior to concomitant exposure of 18.0 ms (95% CI 3.5–32.5; p < 0.05) was found in the hydroxychloroquine monotherapy cohort. QTc changes varied considerably across cohorts, with standard deviations ranging from 40.9 (hydroxychloroquine monotherapy) to 57.8 (hydroxychloroquine + sulfasalazine). There was no difference in QTc measurements among cohorts. The hydroxychloroquine + QTc-prolonging agent cohort had the highest average Tisdale Risk Score compared with those without concomitant exposure (p < 0.05). CONCLUSION: Our analysis of retrospective electronic health records found hydroxychloroquine to be associated with a moderate increase in the QTc interval compared with sulfasalazine or methotrexate. However, the QTc was not significantly increased with concomitant exposure to other drugs known to increase QTc interval.
format Online
Article
Text
id pubmed-9167427
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-91674272022-06-07 QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data Villa Zapata, Lorenzo Boyce, Richard D. Chou, Eric Hansten, Philip D. Horn, John R. Gephart, Sheila M. Subbian, Vignesh Romero, Andrew Malone, Daniel C. Drugs Real World Outcomes Original Research Article INTRODUCTION: Hydroxychloroquine can induce QT/QTc interval prolongation for some patients; however, little is known about its interactions with other QT-prolonging drugs. OBJECTIVE: The purpose of this retrospective electronic health records study was to evaluate changes in the QTc interval in patients taking hydroxychloroquine with or without concomitant QT-prolonging medications. METHODS: De-identified health records were obtained from the Cerner Health Facts(®) database. Variables of interest included demographics, diagnoses, clinical procedures, laboratory tests, and medications. Patients were categorized into six cohorts based on exposure to hydroxychloroquine, methotrexate, or sulfasalazine alone, or the combination of any those drugs with any concomitant drug known to prolong the QT interval. Tisdale QTc risk score was calculated for each patient cohort. Two-sample paired t-tests were used to test differences between the mean before and after QTc measurements within each group and ANOVA was used to test for significant differences across the cohort means. RESULTS: A statistically significant increase in QTc interval from the last measurement prior to concomitant exposure of 18.0 ms (95% CI 3.5–32.5; p < 0.05) was found in the hydroxychloroquine monotherapy cohort. QTc changes varied considerably across cohorts, with standard deviations ranging from 40.9 (hydroxychloroquine monotherapy) to 57.8 (hydroxychloroquine + sulfasalazine). There was no difference in QTc measurements among cohorts. The hydroxychloroquine + QTc-prolonging agent cohort had the highest average Tisdale Risk Score compared with those without concomitant exposure (p < 0.05). CONCLUSION: Our analysis of retrospective electronic health records found hydroxychloroquine to be associated with a moderate increase in the QTc interval compared with sulfasalazine or methotrexate. However, the QTc was not significantly increased with concomitant exposure to other drugs known to increase QTc interval. Springer International Publishing 2022-06-05 /pmc/articles/PMC9167427/ /pubmed/35665910 http://dx.doi.org/10.1007/s40801-022-00307-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Villa Zapata, Lorenzo
Boyce, Richard D.
Chou, Eric
Hansten, Philip D.
Horn, John R.
Gephart, Sheila M.
Subbian, Vignesh
Romero, Andrew
Malone, Daniel C.
QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data
title QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data
title_full QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data
title_fullStr QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data
title_full_unstemmed QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data
title_short QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data
title_sort qtc prolongation with the use of hydroxychloroquine and concomitant arrhythmogenic medications: a retrospective study using electronic health records data
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167427/
https://www.ncbi.nlm.nih.gov/pubmed/35665910
http://dx.doi.org/10.1007/s40801-022-00307-5
work_keys_str_mv AT villazapatalorenzo qtcprolongationwiththeuseofhydroxychloroquineandconcomitantarrhythmogenicmedicationsaretrospectivestudyusingelectronichealthrecordsdata
AT boycerichardd qtcprolongationwiththeuseofhydroxychloroquineandconcomitantarrhythmogenicmedicationsaretrospectivestudyusingelectronichealthrecordsdata
AT choueric qtcprolongationwiththeuseofhydroxychloroquineandconcomitantarrhythmogenicmedicationsaretrospectivestudyusingelectronichealthrecordsdata
AT hanstenphilipd qtcprolongationwiththeuseofhydroxychloroquineandconcomitantarrhythmogenicmedicationsaretrospectivestudyusingelectronichealthrecordsdata
AT hornjohnr qtcprolongationwiththeuseofhydroxychloroquineandconcomitantarrhythmogenicmedicationsaretrospectivestudyusingelectronichealthrecordsdata
AT gephartsheilam qtcprolongationwiththeuseofhydroxychloroquineandconcomitantarrhythmogenicmedicationsaretrospectivestudyusingelectronichealthrecordsdata
AT subbianvignesh qtcprolongationwiththeuseofhydroxychloroquineandconcomitantarrhythmogenicmedicationsaretrospectivestudyusingelectronichealthrecordsdata
AT romeroandrew qtcprolongationwiththeuseofhydroxychloroquineandconcomitantarrhythmogenicmedicationsaretrospectivestudyusingelectronichealthrecordsdata
AT malonedanielc qtcprolongationwiththeuseofhydroxychloroquineandconcomitantarrhythmogenicmedicationsaretrospectivestudyusingelectronichealthrecordsdata